Breastfeeding is important for the development of the child. Many antibiotics are considered safe during breastfeeding. The aim of the study was to assess the quality of lactation studies with antibiotics using the FDA and International Lactation Consultant Association quality guidelines for lactation studies. The secondary goal was to determine the exposure of the breastfed infant to antibiotics in relation to bacterial resistance and the developing microbiome. A literature search was performed and the included studies were scored on methodology, parameters concerning maternal exposure to antibiotics, maternal plasma and milk sampling. The infant exposure has been calculated and expressed as a percentage of a normal infant therapeutic dose. Sixty-six studies were included in five antibiotic groups (broad-spectrum penicillin, cephalosporins, macrolides and lincosamides, quinolones and sulphonamides). Cephalosporins were the most studied group of antibiotics (n = 21). Fifteen studies met all the criteria of "mother exposure to antibiotic". Six studies met every criterion related to "plasma sampling". Only one case report met all listed criteria for lactation studies. The correct calculation of infant exposure to antibiotics via the milk:plasma ratio (AUC) varies between 13% for macrolides and 38% for broad-spectrum penicillin. The highest assessed exposure as a percentage of infant therapeutic dose was for metronidazole (11%). The studies meet to a limited extent with the quality standards for lactation research. The breastfed infants are exposed to a subtherapeutic concentration of antibiotics.
| INTRODUCTION
Breastfeeding has numerous advantages over infant formula milk for the development of the neonate and decreases health risks of the nursing mother. Breastfeeding protects the neonate against child infections and malocclusions, increased intelligence at later age and protects against overweight and diabetes. For the mother, breastfeeding protects against breast cancer, ovarian cancer and type II diabetes. 1 The World Health Organization recommends breastfeeding exclusively during the first 6 months and as a supplement up to 2 years. This is due to the earlier mentioned benefits and the low costs for the developing world. In the United States, 75% of mothers breastfeed their infants in the early post-partum period and 36% are exclusively breastfeeding at 3 months. 2 One of the concerns in the lactation period is the safety of drugs being used by mothers, because transfer of the drug over the mammary gland may lead to side effects in the suckling infant. Antibiotics are probably among the most prescribed drugs during lactation. The prevalence of mastitis treated with antibiotics in lactating women is estimated between 16 and 49%. 3, 4 Most antibiotics are considered to be safe during breastfeeding, except quinolones, chloramphenicol, aminoglycosides during early post-natal period and possibly metronidazole. 5, 6 Nowadays, resistance to antibiotic drugs forms a great problem. Studies in both human beings and animals show that low-dose exposure or inadequate exposure time to antibiotics correlates to the development of resistant microbes. [7] [8] [9] Therefore, (long-term) subtherapeutic transmission of antibiotics via breast milk to the infant could possibly contribute to antibiotic resistance in the infant. However, no data establishing this relation could be found. Furthermore, recent research shows that the neonatal microbiome is affected by intrapartum antibiotics [10] [11] [12] [13] and maternal use of antibiotics in the lactation period. 14 In turn, the microbiome may affect brain development, behaviour and obesity. [15] [16] [17] To assess the safety of antibiotics in the light of the developing microbiome, it is of paramount importance to know the amount of antibiotics transferred into breast milk which reaches the neonatal gastrointestinal tract. The most important parameter for the exposure of an infant to maternal use of antibiotics is the Absolute Infant Dose (AID) of which the formula is described in Figure 1 . By calculating the AID, the infant dose per kilogram per day is known. Furthermore, the AID can be compared with the Therapeutic Infant Dose.
| OBJECTIVE AND RATIONALE
In this study, we aimed, using guidelines of the FDA 18 and ILCA, 19 to determine the quality of lactation studies that investigated antibiotics in breast milk and examined the data regarding Absolute Infant Dose. 
| Inclusion and exclusion criteria
Only articles containing primary data in human beings published from 1970 until March 2017 were included in this study. We excluded studies of languages other than English, German and Dutch. Studies without reported drug concentrations in the mother's plasma or mother's milk were also excluded.
| Guidelines
The FDA 18 and ILCA 19 draft guidelines were used to review the quality of the included articles. These guidelines provide recommendations on how to conduct clinical lactation studies. In more detail, information is given about the recommended study design and the data analysis that is favoured. In this MiniRreview, the recommendations of the FDA and ILCA were combined to create a checklist (Table 1) . Due to the limited amount of studies available per antibiotic, solely the results of antibiotic groups containing a minimum of five papers are presented in this study ( Figure 3 ).
| Absolute Infant Dose
We determined the AIDs that are known for each group of antibiotics, using the reported values or by calculating using the formula provided in Figure 1 , using 150 mL/kg/d as a standard for daily milk intake. 20 We used a mean value for the AID for two published reports and a median value for three or more reports. The AID as a percentage of the Therapeutic Infant Dose (mg/kg/d) was calculated using the paediatric drug formulary of the Netherlands. 21 4 | OUTCOME 174 articles and 797 articles were excluded in LactMed and PubMed, respectively. Reasons for exclusion were different language (n = 127), no concentrations (n = 254), review (n = 169), animal study (n = 258), paper published before 1970 (n = 38), already in LactMed database (n = 76) and duplicates (n = 49; Figure 2 ). We found no studies that met the inclusion criteria for the antibiotics of the groups "Trimethoprim and similar compounds" and "Polymixins" ( Table 2 ). In total, 66 studies
were assessed using the checklist based on FDA 18 and ILCA 19 guidelines (Table 1) . For five antibiotic groups, only one study [22] [23] [24] [25] [26] was included and for three antibiotic groups, two studies [27] [28] [29] [30] were included. The results of the quality determination of the different parameters (Table 1) of six antibiotic groups with at least five studies are shown in Figure 3A -D. The parameters ( guidelines are the reported daily dose and dose regimen (see Figure 3A) . Shortcomings of most studies were the absence of whole milk portions ( Figure 3B ). Fifteen studies 22, 26, 28, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] met all the criteria of "mother exposure to drug"; this includes the presence of the administered daily dose and dose regimen, the analysis of concentrations during steady state and the use of longitudinal data (Table 1 ). In only one case report study with cephalexin, 31 the breast milk sampling met all listed criteria. In six of the 66 assessed studies, 36, 37, 41, [43] [44] [45] every criterion related to "plasma sampling" (Table 1 ) was present. Only one study with cephalexin 31 met all the criteria of "method/data analysis", including M:P, RID and AID are correctly measured, and a validated method of analysis is used. Infant's plasma concentrations or the occurrence of adverse reactions in the breastfeeding infant were only addressed in 10 of the 66 assessed studies. 22, 30, 31, 41, 44, [46] [47] [48] [49] [50] Next to the quality determination, we also assessed the potential infant risk based on the Absolute Infant Dose (AID) for different antibiotic drugs ( Figure 4A 
| WIDER IMPLICATIONS
Of all assessed antibiotic groups, cephalosporins were the most documented group, with 21 different studies, including 226 patients ( Table 2 ). The data on the quality determination ( Figure 3 ) also reveal a prominent place for cephalosporins in relation to the validation criteria (Table 1 ). This could be related to the fact that cephalosporins are frequently used antibiotics in hospitals and especially in gynaecological care departments, [55] [56] [57] with attendance of nursing mothers. Most other antibiotics are poorly studied like broad-spectrum penicillins (eight studies, 78 patients), sulphonamides (five studies, 27 patients) macrolides and lincosamides (eight studies, 67 patients) and quinolones (seven studies, 59 patients).
Many studies lack information about the sample size, method of collection (electric pump or "normal") and whether foremilk or hindmilk was sampled. Without a standardized method of collection, it is hard to compare studies examining transfer of drugs into breast milk. A differentiation between foremilk and hindmilk collection is necessary, which was only performed in six studies. 29, 31, 40, [58] [59] [60] Hindmilk is more lipophilic than foremilk; therefore, lipophilic antibiotics such as quinolones, macrolides and tetracyclines will probably penetrate more easily into hindmilk. [61] [62] [63] This might result in an under-or over-estimation of antibiotic concentrations in breast milk. Calculated parameters related to drug transfer into breast milk (M:P ratio, AID, RID) are poorly studied in the assessed lactation studies. The correct measurement of the M:P ratio varies between 13% of the studies for macrolides and lincosamides and 38% of the studies for broad-spectrum penicillin. The M:P ratio is often calculated as single point milk:plasma concentrations, where whole "area under the curve" of the milk/plasma curve is by far more accurate. However, the clinical implication of the M:P ratio is over-estimated because a low absolute dose with a high M: P ratio means that still a small amount of a particular drug can be found in the milk. The poor establishment of drug transport over the mammary gland may be related to the absence of measurements in steady-state conditions and concurrent sampling of plasma and milk in many studies. In order to assess the infant risk to different antibiotics, when transferred into breast milk, we presented, or when necessary, calculated the Absolute Infant Dose (AID). The highest exposure in breast milk was found for sulphapyridin (2.68 mg/kg/d) based on an average milk intake of 150 mL/kg/d. This sulphonamide seems compatible with breastfeeding, when the infant shows no signs of illness, stress or jaundices. 5, 64, 65 However, based on primarily the AID, it is hard to review the risk for the infant. Therefore, we calculated the AID as a percentage of the daily therapeutic dose. The AID in perspective of the Therapeutic Infant Dose for metronidazole (11% of therapeutic dose), ofloxacin (2% of therapeutic dose) and gentamycin (2% of therapeutic dose; Figure 4B ) would relate to the highest risk for the breastfeeding infant. For metronidazole, which is indicated for anaerobic infections, especially for prophylaxis following caesarian section and post-partum infection control, [66] [67] [68] no breastfeeding is advised upon 12-24 hours after the last metronidazole dose. 65 However, only one case report describes infant diarrhoea after breast milk consumption of a mother exposed to metronidazole. 69 Based on these percentages alone, it is hard to predict any infant side effects. Therefore, we would like to emphasize that like for most drugs, minimalizing infant exposure also applies for maternal use of antibiotics and monitoring for possible adverse reactions is needed. However, only in six studies, adverse reactions were documented using standardized methods. 22, 30, 31, 41, 46, 48 A mean AID based on data from two different studies was calculated for tetracycline, chloramphenicol, ceftriaxone, ciprofloxacin and tinidazole. A median AID based on data from three different studies was calculated for cefotaxime, cephalexin, clindamycin, azithromycin, metronidazole, and nitrofurantoin. A median AID based on data from four different studies was calculated for sulphapyridin, cefoxitin and ampicillin Diarrhoea, irritability and pyloric stenosis have been reported for erythromycin in nursing infants. Perforated pseudomembranous colitis was reported in a breastfed infant whose mother used ciprofloxacin. For sulphasalazine, there is a risk of bilirubin displacing, and bloody diarrhoea has been reported in the nursing infant of a mother who was a slow acetylator. For chloramphenicol, refusal of the breast, somnolence during feeding, gas and post-feeding emesis have been reported in nursing infants. For metronidazole, loose stools, feeding problems and candidiasis have been reported in nursing infants. 64 The use of maternal antibiotics could also play a role in bacterial resistance and modification of the infant microbiome. As mentioned earlier, subtherapeutic dosing of antibiotics is associated with the development of resistant microorganisms. [7] [8] [9] Based on our results, all assessed antibiotics ( Figure 4B ) are transferred into breast milk in subtherapeutic levels ranging from 0.05% for cefotaxime to 10.61% for metronidazole of the Therapeutic Infant Dose. This low-dose exposure might induce antibiotic resistance in the infant and might lead to a reduced diversity of intestinal microbiota during infancy and the occurrence of allergies later in life, [71] [72] [73] and contribute to the development of infant diseases, even later in life, such as disturbances in brain development, immunity, behaviour and obesity. [15] [16] [17] 74, 75 Also, the infant colonization rate of microorganisms is affected by maternal use of antibiotics in the lactation period, 76 which is one of the first signs of altered gut microbiota composition. The safety of maternal use of antibiotics in relation to the infant's microbiome and its effects later in life should be further studied.
| CONCLUSION
This MiniReview assessed the quality of lactation studies according to FDA and ILCA guidelines, and most studies did not comply with these guidelines. In particular, the study methodology was poorly described. We found that antibiotics such as metronidazole with a relatively high AID of 11% of the Therapeutic Infant Dose is suspected of antibiotic resistance and microbiome alterations in the suckling infant. However, further research on these effects in breastfeeding infants is needed. In the meantime, the benefits of maternal antibiotic therapy should be weighed against the potential (long-term) risk for the breastfeeding infant. VAN WATTUM ET AL.
